PIONYR Immunotherapeutics
Acquired
Forging a new path in immuno-oncology.
- Headquarters
- South San Francisco, California
- Employees
- 51–200
- Founded
- 2015
- Business Model
- B2B
- Website
- pionyrtx.com
- Total Funding
- $355.0M
- Last Round
- $275.0M Corporate RoundJun 2020
About
Pionyr Immunotherapeutics was a South San Francisco, California-based clinical-stage biotechnology company founded in 2015. The company's myeloid tuning approach targeted suppressive myeloid cells in the tumor microenvironment using novel antibody therapeutics, offering a differentiated mechanism from checkpoint inhibitors. Pionyr raised $175 million in total funding. Gilead Sciences secured an exclusive acquisition option in 2020 but declined to exercise it. Pionyr was subsequently acquired by Ikena Oncology in August 2023.
Sign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Create Free AccountFunding History
Sign up to view funding details
Create a free account to see full funding history, valuations, and investor participation.
Create Free Account